Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14237093 | 0.85 | ERN1 (0.48) | ERN1MEN1KMT2ALMNATHRB | |
| SCHEMBL172507 | 0.80 | NFE2L2 (0.37) | ERN1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16962801 | 0.80 | ERN1 (0.38) | ERN1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL25544499 | 0.80 | NFE2L2 (0.37) | ERN1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL547944 | 0.79 | MEN1 (0.44) | ERN1MEN1KMT2ALMNATHRB | |
| SCHEMBL91337 | 0.78 | KDM4E (0.45) | MEN1KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL5530294 | 0.78 | ALDH1A1 (0.56) | ERN1MEN1KMT2ALMNATHRB | |
| SCHEMBL24116770 | 0.77 | ERN1 (0.48) | ERN1MEN1KMT2ALMNATHRB | |
| SCHEMBL30266751 | 0.77 | ERN1 (0.48) | ERN1MEN1KMT2ALMNATHRB | |
| SCHEMBL24116929 | 0.77 | ERN1 (0.48) | ERN1MEN1KMT2ALMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115698017-B | Methyl 2-methyl-5-oxo-1, 4,5, 7-tetrahydrofurano [3,4-b ] pyridine-3-carboxylate compounds as CAV1.2 activators | 诺华股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-4165048-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4- B]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | Novartis AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| CN-115698017-A | Methyl 2-methyl-5-oxo-1, 4,5, 7-tetrahydrofuro [3,4-b ] pyridine-3-carboxylate compounds as CAV1.2 activators | 诺华股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11453679-B2 | Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Cav1.2 activators | NOVARTIS AG (CH) | 2022-09-27 | — | — | US | disclosed |
| WO-2021255608-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4- B]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021255608-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4- B]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| US-20210387995-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210387995-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-12-16 | — | — | US | disclosed |
| CN-110062758-A | BICYCLIC DIHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | 奇斯药制品公司 | 2019-07-26 | — | — | CN | disclosed |
| US-20130004894-A1 | UNDER COAT FILM MATERIAL AND METHOD OF FORMING MULTILAYER RESIST PATTERN | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-01-03 | — | — | US | disclosed |
| EP-2535768-A1 | UNDERLAYER FILM MATERIAL, AND METHOD FOR FORMATION OF MULTILAYER RESIST PATTERN | Mitsubishi Gas Chemical Company, Inc. (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| EP-0861223-B1 | PROCESS FOR THE SYNTHESIS OF CURCUMIN-RELATED COMPOUNDS | GENEPRINT INC (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-0861223-A1 | PROCESS FOR THE SYNTHESIS OF CURCUMIN-RELATED COMPOUNDS | Geneprint, Inc. (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5679864-A | REACTING 2,4-DIKETONE WITH COMPLEXING AGENT TO PRODUCE ENOLIC REACTANT, ADDING AROMATIC ALDEHYDE, AMINE CATALYST, NEUTRALIZING | GENE PRINT INC. (US) | 1997-10-21 | — | — | US | disclosed |
| WO-1997016403-A1 | PROCESS FOR THE SYNTHESIS OF CURCUMIN-RELATED COMPOUNDS | GENEPRINT, INC. (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | ERN1 3173/4885MEN1 4867/4885KMT2A 2576/4885 |
| US-11453679-B2 | Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Cav1.2 activators | CACNA1D, CACNA1I, CACNA1S | ERN1 4694/4885MEN1 2827/4885KMT2A 1594/4885 |
| US-20210387995-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | CACNA1D, CACNA1I, CACNA1S | ERN1 4694/4885MEN1 2827/4885KMT2A 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.